Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Prospective, Multicenter, Single-Arm, Pragmatic Interventional Cohort Study Evaluating Real-World Outcomes and Dosing Patterns of Ebglyss (Lebrikizumab) in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

NCT07856134 is registered in ClinicalTrials.gov with Forefront Dermatology S.C as lead sponsor.

NCT NCT07856134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07856134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Prospective, Multicenter, Single-Arm, Pragmatic Interventional Cohort Study Evaluating Real-World Outcomes and Dosing Patterns of Ebglyss (Lebrikizumab) in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
Forefront Dermatology S.C
Phase
Phase 4
Overall status
Not yet recruiting
Start date
November 11, 2026
Completion date
March 31, 2028
Enrollment
250 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis